Off-Label Promotion Not Enough For Fed Intervention – Patton Boggs Lawyer
This article was originally published in The Pink Sheet Daily
Justice Department is unlikely to investigate off-label drug claims unless a firm is also offering kickbacks or bilking Medicare or Medicaid, Laura Laemmle asserts, discussing recent case against drug firm Serono.
You may also be interested in...
Dependence on Boston Scientific's Taxus royaltieis will fall significantly once Angiotech offers AMI's oncology, aesthetic, wound closure and ophthalmology devices.
Allergan may be forced to divest more than Inamed's development-stage botulinum toxin type A product, Reloxin.
Medical advances for devices, vaccines, telomerase inhibitors and disease prevention programs will lead to more rapid cost increases than the rising incidence of chronic disease, according to RAND Corporation.